WO2024121632 - USE OF ANTI-CD117 ANTIBODY DRUG CONJUGATE (ADC)
National phase entry is expected:
Publication Number
WO/2024/121632
Publication Date
13.06.2024
International Application No.
PCT/IB2023/059716
International Filing Date
28.09.2023
Title **
[English]
USE OF ANTI-CD117 ANTIBODY DRUG CONJUGATE (ADC)
[French]
UTILISATION D'UN CONJUGUÉ ANTICORPS-MÉDICAMENT (ADC) ANTI-CD117
Applicants **
CRISPR THERAPEUTICS AG
Inventors
BERTELSEN, Kirk
Priority Data
63/386,891
09.12.2022
US
63/386,919
11.12.2022
US
63/479,535
11.01.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3827 | |
| EPO | Filing, Examination, Granting | 28708 | |
| Japan | Filing, Examination, Granting | 3260 | |
| South Korea | Filing, Examination, Granting | 4256 | |
| USA | Filing, Examination, Granting | 12990 |
Total:
53,041
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to uses of an anti-CD117 antibody drug conjugate (ADC) comprising an anti-CD117 antibody conjugated to an amatoxin via a linker, for targeted conditioning a human patient in need thereof for hematopoietic stem cell (HSC) transplantation. Also provided is a method for depleting CD117+ cells, e.g., endogenous HSCs, in a human patient in need thereof.[French]
L'invention concerne des utilisations d'un conjugué anticorps-médicament (ADC) anti-CD117 comprenant un anticorps anti-CD117 conjugué à une amatoxine par l'intermédiaire d'un lieur, pour le conditionnement ciblé d'un patient humain en ayant besoin pour une transplantation de cellules souches hématopoïétiques (HSC). L'invention concerne également une méthode de déplétion de cellules CD117+, par exemple, des HSC endogènes, chez un patient humain en ayant besoin.